Viewing Study NCT06082167

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:54 AM
Ignite Modification Date: 2026-05-07 @ 11:57 AM
Study NCT ID: NCT06082167
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-08-17
First Post: 2023-10-09
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sponsor: Exelixis
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Head and Neck Squamous Cell Carcinoma View
Keywords: